
Bloomlife
Founded Year
2014Stage
Series B | AliveTotal Raised
$26.83MLast Raised
$12.2M | 7 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+173 points in the past 30 days
About Bloomlife
Bloomlife operates as a women's health company that focuses on improving maternal health through technology in the healthcare sector. The company offers remote patient monitoring and connected devices that provide data analytics for maternal and fetal health, as well as digital health assessments to manage pregnancies. Bloomlife primarily serves healthcare providers and pregnant women. Bloomlife was formerly known as Bloom Technologies. It was founded in 2014 and is based in San Francisco, California.
Loading...
Bloomlife's Product Videos


ESPs containing Bloomlife
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The maternal & fetal health screening market helps to improve patient outcomes by offering remote patient monitoring services & medical devices to diagnose and monitor maternal and fetal health conditions, including maternal preeclampsia, premature birth risk, and fetal oxygenation levels during labor. Some companies supplement their screening products with support services for comprehensive care.…
Bloomlife named as Highflier among 15 other companies, including Babyscripts, Nuvo Group, and Sera Prognostics.
Bloomlife's Products & Differentiators
Bloomlife Pregnancy Tracker
Prenatal wearable that non-invasively measures fetal heart rate, maternal heart rate and uterine activity. Used to assess fetal health for high risk pregnancies through a well established clinical test called a fetal non-stress test.
Loading...
Research containing Bloomlife
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Bloomlife in 1 CB Insights research brief, most recently on Mar 28, 2024.

Mar 28, 2024
The femtech market mapExpert Collections containing Bloomlife
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Bloomlife is included in 4 Expert Collections, including Baby and Kids Tech.
Baby and Kids Tech
1,281 items
Companies developing tech-enabled products and services that primarily serve babies, children up to approximately 12 years old, and their parents.
Smart Home & Consumer Electronics
1,234 items
This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.
Digital Health
11,305 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Women's Health Tech
698 items
This collection includes companies applying technology to address a spectrum of physical, mental, and social well-being concerns specific to women. Examples include companies in reproductive health, maternal care, fertility tracking, and menopause support.
Bloomlife Patents
Bloomlife has filed 3 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/31/2014 | 5/7/2019 | Midwifery, Obstetrics, Sensors, Tests during pregnancy, Childbirth | Grant |
Application Date | 7/31/2014 |
---|---|
Grant Date | 5/7/2019 |
Title | |
Related Topics | Midwifery, Obstetrics, Sensors, Tests during pregnancy, Childbirth |
Status | Grant |
Latest Bloomlife News
Nov 1, 2024
By News Desk Published On: November 1, 2024Last Updated: November 1, 2024 The National Institutes of Health has announced winners of the Rapid Acceleration of Diagnostics Technology (RADx® Tech) Fetal Monitoring Challenge , a $2 million prize competition to speed development of innovative medical technologies for foetal health diagnosis, detection and monitoring. Judging of six finalists in the technology development sprint phase of the challenge produced three top winners — a device to detect foetal stress, an AI model for early detection of congenital heart disease (CHD) and a wearable ultrasound patch to monitor fetal vascular health — plus three technologies taking runner-up honours. The multi-phase competition sought to advance accessible and cost-effective point-of-care and home-based devices that measure fetal health indicators and are implementable in low-resource settings both within the United States and internationally. The RADx Tech Fetal Monitoring Challenge targeted unacceptably high stillbirth rates and poor foetal health outcomes. Globally, about two million stillbirths occur each year, with 40 per cent occurring after the onset of labour. Innovation in diagnostic technology development can lead to earlier and more accurate diagnosis, detection and monitoring of foetal health status and enable appropriate medical intervention. NIBIB Director Bruce J. Tromberg, PhD, said: “The Fetal Monitoring Challenge leverages NIBIB’s RADx Tech accelerator platform and innovation funnel approach to speed innovative technologies through the development pipeline. “Those teams that engaged with us and achieved this prize are to be congratulated for meeting the challenge to innovate for improved foetal and neonatal health outcomes in this country and around the world.” More than 40 competition entrants, including start-ups, medium-sized companies and academic investigators, sought prizes through months of performance assessment and milestone-based interim awards. Throughout the process, participants received technical support through the RADx Tech programme as they worked to mature their technologies and reduce risks that could derail commercialisation. Finalists were awarded first, second and third-place prizes of $750,000, $400,000, and $200,000 respectively, while three runner-up teams win prizes of $50,000 each. When combined with previous interim prizes, the challenge will have awarded a total of $2 million. The winning technologies are as follows: First place — $750,000 Lumerah: a transabdominal foetal pulse oximeter LumerahTM is a non-invasive, transabdominal foetal pulse oximeter that measures the foetal arterial blood oxygen saturation. This technology could improve the detection of foetal distress due to foetal hypoxia during labour and delivery. It can also be utilised during the third trimester of pregnancy to assess the foetus during nonstress tests and biophysical profiles. The technology could also provide benefits as a research tool to address disparities in maternal healthcare delivery and the etiologies of intrauterine growth restriction, preterm labor, and stillbirth. Second place — $400,000 Deep learning model for detection of congenital heart disease This technology addresses complex congenital heart disease (CHD), which requires surgery or other interventions within the first year of life. The research team developed and demonstrated a deep learning model for early CHD detection from foetal ultrasound imaging. Prenatal CHD diagnosis could enable foetal therapy and provide better options for birth planning, timely cardiology referrals, interventional planning, and downstream therapeutic options. Third place — $200,000 A wearable ultrasound patch Softsonics is developing a wearable ultrasound patch to continuously monitor hemodynamics in the placenta, umbilical cord, and foetal vessels throughout gestation. The technology is intended to deliver insights into foetal physiology and pathophysiology and enable the early detection of foetuses at risk of complications, injuries, and stillbirth. Each of the following technology developers will receive runner-up prizes of $50,000: Bloomlife, San Francisco Wearable patch for foetal monitoring This wearable patch device leverages highly sensitive sensors combined with advanced signal processing for foetal heart rate monitoring and foetal movement assessment. The device could be used to identify early signs of foetal distress that may lead to brain damage or stillbirth. Bloomlife plans to expand use of the device to improve access to foetal monitoring for all high-risk pregnancies, regardless of geographical location and socio-economic status. Mayo Clinic, Rochester, Minnesota Quantitative micro-miniature intrapartum monitor (QMIM) QMIM is a miniaturized predictive device capable of real-time and minimally invasive monitoring of foetal physiology during labour and delivery. Heart rate and pulse oximetry are extracted from waveforms that are processed and analysed by algorithms generated through a machine-learning framework. QMIM could enable the identification of data that predict problematic foetal cardiovascular functions. QMIM’s sensor requires only a mobile phone application for interpretation. Storx Technologies, Davis, California Transabdominal Foetal Oximetry This technology can enable non-invasive measurement of foetal arterial blood oxygen saturation through the maternal abdomen, thereby assisting providers in assessment of foetal wellbeing during labour and delivery. TFO may potentially lead to improvement in the accuracy of detecting babies at risk of birth asphyxia, reduction of unnecessary intrapartum interventions associated with today’s foetal monitoring approaches with poor specificity, and enhanced monitoring of at-risk pregnancies earlier in the gestational period.
Bloomlife Frequently Asked Questions (FAQ)
When was Bloomlife founded?
Bloomlife was founded in 2014.
Where is Bloomlife's headquarters?
Bloomlife's headquarters is located at 1931 McAllister Street, San Francisco.
What is Bloomlife's latest funding round?
Bloomlife's latest funding round is Series B.
How much did Bloomlife raise?
Bloomlife raised a total of $26.83M.
Who are the investors of Bloomlife?
Investors of Bloomlife include SOSV, HAX, 15th Rock Ventures, Noshaq, Kapor Capital and 18 more.
Who are Bloomlife's competitors?
Competitors of Bloomlife include Baymatob, Raydiant Oximetry, Nuvo Group, Biorithm, Kali Healthcare and 7 more.
What products does Bloomlife offer?
Bloomlife's products include Bloomlife Pregnancy Tracker.
Loading...
Compare Bloomlife to Competitors

Marani Health operates as an artificial intelligence (AI)-powered maternal healthcare technology company focused on improving patient outcomes and enhancing clinical workflows in the healthcare sector. The company offers a platform that delivers individual insights through connected devices, enabling personalized and proactive care for pregnant individuals. Marani Health primarily serves maternity providers, health plans, employers, and patients with its solutions for prenatal and postpartum care. Marani Health was formerly known as Odonata Health. It was founded in 2018 and is based in Oakdale, Minnesota.

Baymatob develops artificial intelligence-guided solutions aimed at enhancing maternal and neonatal health outcomes. The company offers a wearable sensor named Oli, which monitors complex physiological information to provide early warnings for complications like postpartum hemorrhage. It primarily serves the healthcare sector. The company was founded in 2017 and is based in Leichhardt, Australia.

Raydiant Oximetry focuses on improving maternal-fetal medicine by developing noninvasive sensor technology for childbirth. Its main product, Lumerah™, is a fetal pulse oximeter designed to measure fetal oxygen levels accurately and reduce unnecessary cesarean deliveries. The company primarily serves the healthcare sector, offering tools for obstetric providers to evaluate fetal well-being during labor. It was founded in 2016 and is based in San Ramon, California.

Babyscripts focuses on improving maternal health outcomes through technology and operates within the healthcare sector. The company offers a risk detection program that includes remote patient monitoring, perinatal education, and mental health assessments to support expectant and new mothers. Babyscripts primarily serves healthcare providers, including hospitals, physicians, midwives, birth centers, and health plans, with virtual tools designed to enhance patient care and outcomes in maternity care. It was founded in 2014 and is based in Washington, District of Columbia.
NeoPrediX specializes in the development of clinical decision support software within the healthcare technology sector. Their products leverage predictive analytics to enhance decision-making in women's health and neonatal care, focusing on early detection of health risks and personalization of patient care. It was founded in 2020 and is based in Basel, Switzerland.

Coroflo develops a breastfeeding monitor that is integrated into a nipple shield, measuring and displaying how much breastmilk a baby receives during feeding sessions. The product connects to a mobile application to provide data on milk flow and transfer. It was founded in 2016 and is based in Dublin 11, Ireland.
Loading...